STOCK TITAN

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Exelixis (Nasdaq: EXEL) announced management participation in two upcoming investor conferences. The first is at the BofA Securities 2022 Healthcare Conference on May 11 at 1:40 p.m. ET in Las Vegas, followed by the RBC Capital Markets Global Healthcare Conference on May 17 at 8:30 a.m. ET in New York. Interested parties can access webcasts via www.exelixis.com. Replays will be available for 30 days.

Positive
  • None.
Negative
  • None.

- Presentations to be webcast on www.exelixis.com -

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May:

  • BofA Securities 2022 Healthcare Conference: Exelixis is scheduled to present at 1:40 p.m. ET / 10:40 a.m. PT on Wednesday, May 11, 2022 in Las Vegas.
  • 2022 RBC Capital Markets Global Healthcare Conference: Exelixis is scheduled to present at 8:30 a.m. ET / 5:30 a.m. PT on Tuesday, May 17, 2022 in New York.

To access the webcast links, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentations to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for at least 30 days.

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S. trademarks of Exelixis.
COTELLIC is a registered trademark of Genentech, Inc.
MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Investors Contact:

Varant Shirvanian

Associate Director, Investor Relations

Exelixis, Inc.

650-837-7917

vshirvanian@exelixis.com

Media Contact:

Hal Mackins

For Exelixis, Inc.

415-994-0040

hal@torchcommunications.com

Source: Exelixis, Inc.

FAQ

What conferences will Exelixis participate in May 2022?

Exelixis will participate in the BofA Securities 2022 Healthcare Conference on May 11 and the RBC Capital Markets Global Healthcare Conference on May 17.

What are the presentation times for Exelixis at the investor conferences?

Exelixis is scheduled to present at 1:40 p.m. ET on May 11 and at 8:30 a.m. ET on May 17.

Where can I find the webcast for Exelixis' presentations?

The webcast links for Exelixis' presentations are available at www.exelixis.com.

How long will replays of Exelixis' presentations be available?

Replays of Exelixis' presentations will be available for 30 days.

Exelixis Inc

NASDAQ:EXEL

EXEL Rankings

EXEL Latest News

EXEL Stock Data

9.52B
281.04M
1.59%
89.36%
2.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
ALAMEDA